Original Article
Neuropsychopharmacology (2005) 30, 974–983, advance online publication, 23 February 2005; doi:10.1038/sj.npp.1300674
Clinical Research
Altered Expression of 14-3-3 Genes in the Prefrontal Cortex of Subjects with Schizophrenia
Frank A Middleton1,2, Lansha Peng3, David A Lewis3,4, Pat Levitt3,5 and Karoly Mirnics1,3
- 1Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 2Department of Neuroscience & Physiology, State University of New York, Upstate Medical University, Syracuse, NY, USA
- 3Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 4Department of Neuroscience, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- 5John F Kennedy Center for Human Development and Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA
Correspondence: Dr K Mirnics, Department of Psychiatry, University of Pittsburgh School of Medicine, W1655 BST, 3811 O'Hara St, Pittsburgh, PA 15213, USA. Tel: +1 412 648 9788; Fax: +1 412 6249910; E-mail: karoly+@pitt.edu
Received 25 October 2004; Revised 30 November 2004; Accepted 7 December 2004; Published online 23 February 2005.
Abstract
Seven distinct 14-3-3 proteins are expressed in mammals. One of the 14-3-3 genes (eta) has been previously associated with decreased expression in the prefrontal cortex (PFC) of subjects with schizophrenia. DNA microarray analysis of the PFC of 10 subjects with schizophrenia and 10 matched controls indicated that the majority of 14-3-3 genes exhibited moderate to marked decreases in expression in schizophrenia, which were significant at the group level across all 10 comparisons (p<0.021). Selected changes in gene expression were further examined using in situ hybridization (ISH) in the same subject pairs as well as in four monkeys treated chronically with haloperidol and matched control animals. All analyses were performed blind to subject identity and diagnosis, or treatment. ISH analysis and multivariate analysis of covariance confirmed the significant decreases in expression of two 14-3-3 genes: beta -31.9%, zeta -18.2%. Two other 14-3-3 genes exhibited more modest decreases in expression levels that were significant only in pairwise comparisons that did not factor in post-mortem interval or tissue storage time: gamma -11.9%, eta -15.4%. In the PFC of haloperidol-treated monkeys, there was no difference in 14-3-3 zeta expression, while 14-3-3 beta increased 28% (p<0.05) as a result of neuroleptic treatment. Our results suggest that decreased expression of selected 14-3-3 genes is a common feature of schizophrenia and that the 14-3-3 beta transcript may be unique among the 14-3-3 genes in its increase in response to haloperidol and decrease in the disease state.
Keywords:
DNA microarray, schizophrenia, haloperidol, prefrontal cortex, in situ hybridization, gene expression
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia
Nature Neuroscience Perspective (01 Jun 2004)
Stress signalling pathways that impair prefrontal cortex structure and function
Nature Reviews Neuroscience Review (01 Jun 2009)
Progress in the use of microarray technology to study the neurobiology of disease
Nature Neuroscience Perspective (01 May 2004)
RESEARCH
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Nature Genetics Letter (01 Oct 1999)
Molecular Psychiatry Original Article

